CEDILANID-D Drug Patent Profile
✉ Email this page to a colleague
When do Cedilanid-d patents expire, and when can generic versions of Cedilanid-d launch?
Cedilanid-d is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in CEDILANID-D is deslanoside. Additional details are available on the deslanoside profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CEDILANID-D?
- What are the global sales for CEDILANID-D?
- What is Average Wholesale Price for CEDILANID-D?
Summary for CEDILANID-D
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Patent Applications: | 963 |
| DailyMed Link: | CEDILANID-D at DailyMed |
US Patents and Regulatory Information for CEDILANID-D
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | CEDILANID-D | deslanoside | INJECTABLE;INJECTION | 009282-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
